Core Viewpoint - Citigroup's report indicates that Innovent Biologics (01801.HK) achieved a 38% year-on-year revenue increase to 13 billion RMB, with a net profit of 834 million RMB, marking a turnaround from losses [1] Financial Performance - Revenue for Innovent Biologics rose to 13 billion RMB, reflecting a 38% increase compared to the previous year [1] - The company reported a net profit of 834 million RMB, indicating a return to profitability [1] Management Guidance - Management reiterated the sales target of 20 billion RMB for 2027 [1] - Despite recent price adjustments and increased competition, sales of Mazdutide continue to show strong momentum [1] Analyst Adjustments - Citigroup raised its revenue forecasts for the company by 24% and 23% for this year and next year, respectively [1] - Earnings per share estimates were increased by 33% and 5% for the respective years [1] - The target price for Innovent Biologics was adjusted from 110 HKD to 115 HKD, maintaining a "Buy" rating [1] Market Position and Ratings - Innovent Biologics has a market capitalization of 143.24 billion HKD, ranking second in the biopharmaceutical sector [1] - Over the past 90 days, seven investment banks have issued "Buy" ratings for the stock, with an average target price of 117.57 HKD [1] - The latest report from Ping An International also gives Innovent Biologics a "Buy" rating with a target price of 110 HKD [1]

Core Viewpoint - The report from CMB International highlights the strong sales performance of BeiGene (06160.HK) in Q4, with a significant year-over-year increase in revenue and profitability, indicating a positive outlook for the company and maintaining a "Buy" rating. Financial Performance - BeiGene's sales of Zebrutinib reached $1.1 billion in Q4, representing a year-over-year increase of 38% and a quarter-over-quarter increase of 10% [1] - Sales in the U.S. amounted to $845 million, with a year-over-year increase of 37% and a quarter-over-quarter increase of 14% [1] - The gross margin improved by 4.7 percentage points year-over-year to 90.5% [1] - General and administrative expenses decreased by 7.7 percentage points year-over-year [1] - Non-GAAP net profit surged to $225 million year-over-year [1] Future Guidance - The company projects revenue between $6.2 billion and $6.4 billion for 2026 [1] - GAAP operating expenses are expected to be between $4.7 billion and $4.9 billion [1] - Gross margin is anticipated to remain high in the 80% range [1] - Non-GAAP net profit is forecasted to be between $1.4 billion and $1.5 billion [1] Market Position and Analyst Ratings - BeiGene's market capitalization is approximately HKD 274.15 billion, ranking first in the biopharmaceutical II industry [1] - The majority of investment banks maintain a "Buy" rating for the stock, with two firms issuing buy ratings in the last 90 days [1] - The average target price over the last 90 days is HKD 223.43 [1] - Guotai Junan Securities recently issued a "Buy" rating for BeiGene [1]

Group 1 - The chairman of Charoen Pokphand International (03839.HK), Mr. Xie Jiren, has been appointed as an executive director effective from February 24, 2026, due to his new executive role within the group [1] - Mr. Li Shaozhu has resigned as the executive director and CEO (Industrial Business) to focus on personal matters, and he will no longer serve as a member of the board's remuneration committee [1] - Ms. Kobboon Srichai has been appointed as a non-executive director of the company [1] Group 2 - Mr. Ma Deshou has been appointed as the CEO and a member of the remuneration committee following his appointment as an executive director [1] - Mr. Li Shaoqing will remain as an executive director but will no longer serve as the CEO (Biochemical Business) after Mr. Ma's appointment [1] - As of the market close on February 24, 2026, Charoen Pokphand International (03839.HK) was trading at HKD 6.68, down 0.15%, with a trading volume of 128,000 shares and a turnover of HKD 856,200 [1] Group 3 - Charoen Pokphand International has a market capitalization of HKD 1.61 billion and ranks 37th in the biopharmaceutical II industry [1] - There has been low attention from investment banks regarding this stock, with no ratings provided in the last 90 days [1]

Group 1 - The core viewpoint of the article is the strategic cooperation agreement signed between China National Pharmaceutical Group Beikong Biotechnology (08247.HK) and Guangdong Xiaoshou Medical Technology Co., Ltd. to enhance grassroots medical services and resource allocation [1] - The agreement aims to promote multi-dimensional collaboration in the grassroots healthcare sector, focusing on improving the quality of medical resources and service capabilities [1] - As of February 11, 2026, the stock price of China National Pharmaceutical Group Beikong Biotechnology closed at HKD 5.02, reflecting a 0.4% increase with a trading volume of 108,000 shares and a turnover of HKD 544,600 [1] Group 2 - The market capitalization of China National Pharmaceutical Group Beikong Biotechnology is HKD 321 million, ranking 47th in the biopharmaceutical II industry [1] - There has been low attention from investment banks regarding this stock, with no ratings provided in the past 90 days [1]

Core Viewpoint - Rongchang Biologics (09995.HK) anticipates significant revenue growth and profitability turnaround in 2025, projecting a revenue increase of approximately RMB 1.533 billion, representing a year-on-year growth of about 89% [1] Financial Projections - The company expects to achieve an operating revenue of approximately RMB 3.25 billion in 2025, compared to the previous year [1] - Net profit attributable to the parent company is projected to be around RMB 716 million, indicating a return to profitability [1] - The net profit after deducting non-recurring gains and losses is estimated at approximately RMB 78.5 million, also reflecting a turnaround from losses [1] Stock Performance - As of January 30, 2026, Rongchang Biologics closed at HKD 84.2, down 0.41%, with a trading volume of 2.8142 million shares and a turnover of HKD 238 million [1] - The stock has received a majority "buy" rating from investment banks, with four firms issuing "buy" ratings in the last 90 days [1] - The average target price over the last 90 days is HKD 108.33, with a recent report from Zhongtai International giving a target price of HKD 114 [1] Market Position - Rongchang Biologics has a market capitalization of HKD 17.636 billion, ranking 8th in the biopharmaceutical sector [1]

Core Viewpoint - Nocera Biopharma (09969.HK) is expected to achieve significant revenue growth and profitability in 2025, marking a turnaround from previous losses [1] Financial Performance - The company anticipates total revenue of approximately RMB 2.365 billion for 2025, representing a growth of around 134% compared to the previous year [1] - Nocera Biopharma expects to report a net profit attributable to shareholders of approximately RMB 633 million, an increase of about RMB 1.074 billion compared to the previous year [1] - The projected net profit, excluding non-recurring items, is expected to be around RMB 534 million, which is an increase of approximately RMB 974 million year-on-year [1] Stock Performance and Analyst Ratings - As of January 29, 2026, Nocera Biopharma's stock closed at HKD 11.62, down 0.43%, with a trading volume of 3.5789 million shares and a turnover of HKD 41.54 million [1] - The majority of investment banks have a "buy" rating on the stock, with three firms issuing buy ratings in the last 90 days and a target average price of HKD 17.9 [1] - Guoyuan International Holdings has given a buy rating with a target price of HKD 16.81 [1] Market Position - Nocera Biopharma has a market capitalization of HKD 17.433 billion and ranks 9th in the biopharmaceutical industry [1]

Group 1 - Morgan Stanley reported that the stock price of Innovent Biologics (01801.HK) fell by approximately 7% on Monday, which may be related to the recently announced National Reimbursement Drug List (NRDL) [1] - The investment bank maintains an "Overweight" rating on the stock, with nearly 12 investment firms issuing buy ratings in the past 90 days, and the average target price over this period is HKD 118.29 [1] - CITIC Securities recently provided a buy rating for Innovent Biologics with a target price of HKD 136.12 [1] Group 2 - Innovent Biologics has a market capitalization of HKD 147.301 billion and ranks second in the biopharmaceutical II industry [2]

Macro Strategy - The LPR remained unchanged in November, with the 1-year and 5-year rates at 3.00% and 3.50% respectively, indicating stable monetary policy despite weak macro data in October [2][3] - A-share indices experienced significant declines from November 17 to 21, with the Shanghai Composite Index down 3.90% and the ChiNext Index down 6.15%, primarily due to reduced expectations for a December rate cut by the Federal Reserve [3][4] - All primary industries in the A-share market declined, with energy metals and communication equipment showing the highest cumulative gains for 2025 at 83.18% and 78.97% respectively [5][6] Investment Recommendations - For the long term, 2026 is expected to be a year of growth driven by the "14th Five-Year Plan," with a stable A-share market anticipated [7] - Short-term strategies should focus on sectors benefiting from long-term capital inflows, traditional sectors related to "anti-involution," and consumer areas such as motorcycles and medical services [7] North Exchange Overview - As of November 21, 2025, the North Exchange had 284 listed stocks, with an average total market value of 864.16 billion yuan, a decrease of 4.16% from the previous week [10][11] - Notable new listings included Dapeng Industrial, which saw a 1211.11% increase in its stock price during its first week [10][12] Medical Services Industry - The pharmaceutical and biological sector fell by 6.88%, underperforming the Shanghai Composite Index by 3.11 percentage points [16][17] - The medical services sector's PE ratio is currently at 31.22, with a recent decline of 2.25 [18] - High-growth areas such as ADC and TIDES CDMO are recommended for investment, with companies like WuXi AppTec and WuXi Biologics highlighted [19][20][21] Automotive Industry - Yuanrong Qixing showcased 200,000 mass-produced vehicles at the Guangzhou Auto Show, aiming for a cumulative delivery of 1 million vehicles by 2026 [23][24] - The automotive sector is expected to benefit from the acceleration of intelligent technology adoption and supportive policies for vehicle consumption [25][26] - Investment opportunities are significant in the automotive and parts sectors, particularly for companies involved in smart components and electric vehicles [26][27]

Core Viewpoint - Fosun Pharma (02196.HK) announced a partnership agreement to establish a target fund with an investment of RMB 100 million, focusing on strategic emerging sectors such as chemical innovative drugs, biological drugs (including vaccines), high-end medical devices (including IVD), traditional Chinese medicine supplements, and synthetic biology [1]. Group 1: Company Investment and Market Performance - Fosun Pharma's subsidiary will participate as a limited partner (LP) in the target fund, which aims to invest in various strategic sectors [1]. - As of October 28, 2025, Fosun Pharma's stock closed at HKD 23.0, down 2.79%, with a trading volume of 5.34 million shares and a turnover of HKD 123 million [1]. - The stock has a market capitalization of HKD 12.799 billion, ranking 13th in the biopharmaceutical II industry [2]. Group 2: Analyst Ratings and Financial Metrics - The majority of investment banks have a "Buy" rating for Fosun Pharma, with one bank issuing a "Buy" rating in the last 90 days and a target price of HKD 23.2 [1]. - Key financial metrics for Fosun Pharma compared to the biopharmaceutical II industry average include: - ROE: 6.89% (Industry Average: 10.46%, Ranking: 15th) - Revenue: HKD 39.952 billion (Industry Average: HKD 2.54 billion, Ranking: 1st) - Net Profit Margin: 10.81% (Industry Average: -381.46%, Ranking: 14th) - Gross Margin: 47.89% (Industry Average: 59.38%, Ranking: 32nd) - Debt Ratio: 49.26% (Industry Average: 74.41%, Ranking: 33rd) [2].

Macro Strategy - In September, CPI decreased by 0.3% year-on-year and increased by 0.1% month-on-month, with food prices rising by 0.7% and pork prices falling by 17.0%, contributing to a 0.26 percentage point decline in CPI [2][4] - By the end of September, M2 balance reached 335.38 trillion yuan, growing by 8.4% year-on-year, while the total social financing stock was 437.08 trillion yuan, up 8.7% year-on-year [2][4] Healthcare Services Industry - The pharmaceutical and biological sector fell by 1.20%, ranking 25th among 31 primary industries, with the medical services sub-sector dropping 3.37% [6][9] - WuXi AppTec is highlighted as a CRDMO integrated platform company, with its R&D segment driving growth and D&M capacity release significantly increasing revenue per capita from 542,000 yuan in 2018 to an expected 1,118,000 yuan in 2025 [7][8] - The long-term development trend of the healthcare services industry remains positive despite recent geopolitical tensions, with a "buy" rating maintained for the sector [9] Securities Industry - The securities sector showed active performance post-holiday, with the brokerage index rising by 0.5%, outperforming the CSI 300 index by 1 percentage point [11][15] - Daily average stock trading volume reached 25.87 trillion yuan, a 19% increase from the previous period, indicating a significant recovery in trading activity [12][13] - The investment recommendation for the securities industry is to maintain an "overweight" rating, focusing on internet brokerages and firms with strong performance certainty [15] Electronic Industry - OpenAI's release of Sora 2.0 marks a significant milestone in AI applications, with the new video generation model achieving high realism and user engagement [17][19] - The electronic industry is expected to benefit from ongoing recovery in consumer electronics and AI technology advancements, maintaining an "overweight" rating [19] New Materials Industry - The rare earth magnetic materials sector increased by 10.44%, outperforming the benchmark by 8.97 percentage points, while rare earth prices showed mixed trends [21][24] - The investment outlook remains cautious, with a recommendation to maintain an "overweight" rating, focusing on upstream rare earth resource companies and downstream magnetic material firms [25] Banking Industry - Social financing growth slowed to 8.7% in September, with improvements in credit structure, particularly in long-term loans supported by policy measures [28][32] - The banking sector is expected to maintain stable performance, with a recommendation to focus on state-owned banks and regional banks for their investment value [32]